I agree with your sentiment and have personally taken a fast 10% profit with the intent to get back in after a small correction only to miss a ten bagger. I've done it to myself several times, but I won't repeat the same mistake mistake this time.
I believe it's insightful that the company has now expanded the trial sites for P to 25. Not only does this speed up the pace of recruitment and reduce time to trial completion but it minimizes the impact of any one site's failure to follow protocol perhaps much more importantly it sets the stage for the FDA end of trial meeting as the FDA is very concerned about how a drug will perform when prescribed by regular physicians as opposed to the teaching/research physicians at the regional teaching and research hospitals, which is why they require registration studies. This is a very smart move by the Co which large pharma will immediately recognize and one that will add value in partnership negotiations if the trial turns out as we are betting it will. Dr. B was the missing link to the puzzle IMO, I really like the changes that are becoming obvious obvious as they move forward. Just look at their web site as one small example of their increasing maturity and professionalism.
I hope Trumps negative comments about Pharma a few minutes ago does not throw the entire sector into the type of correction Hillary caused by her's on the campaign trail.